<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36772987</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-2300</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The Journal of international medical research</Title><ISOAbbreviation>J Int Med Res</ISOAbbreviation></Journal><ArticleTitle>Implementation effect of a hierarchical pharmaceutical service pattern in patients with systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>3000605231154749</StartPage><MedlinePgn>3000605231154749</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">03000605231154749</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1177/03000605231154749</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This study evaluated the effect of implementing a hierarchical pharmaceutical service pattern based on the knowledge-attitude-practice (KAP) intervention theory on patients with systemic lupus erythematosus.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Eligible patients were randomly divided into an intervention or control group. Pharmaceutical service classification criteria were formulated and used to provide patients with differing levels of pharmaceutical services. The classification scores and KAP levels of patients before and at various time points after the intervention were analyzed. The rates of acute attacks and adverse reactions, related clinical test indices, and disease activity were evaluated in both groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">After 9 months of intervention, the proportions of first- and second-level services in the intervention group declined by 14.43% and 3.94%, respectively, compared with the control group, and the rates of acute attacks and adverse reactions declined by 18.26% and 12.43%, respectively. The KAP level, clinical test indices, and disease activity were significantly different between the groups.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Providing patients with systemic lupus erythematosus with pertinent hierarchical pharmaceutical services based on the KAP theory was instrumental in changing patients' behavior and contributed to facilitating disease self-management, thus improving the quality of pharmaceutical services.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Yinhua</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-5642-8714</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, the First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, the First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, the First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, the First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Chunge</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, the First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Int Med Res</MedlineTA><NlmUniqueID>0346411</NlmUniqueID><ISSNLinking>0300-0605</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010593" MajorTopicYN="Y">Pharmaceutical Services</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Knowledge&#x2013;attitude&#x2013;practice</Keyword><Keyword MajorTopicYN="N">Systemic Lupus Erythematosus Disease Activity Index-2000</Keyword><Keyword MajorTopicYN="N">disease activity</Keyword><Keyword MajorTopicYN="N">effect evaluation</Keyword><Keyword MajorTopicYN="N">hierarchical pharmaceutical service pattern</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>11</Day><Hour>8</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36772987</ArticleId><ArticleId IdType="pmc">PMC9926003</ArticleId><ArticleId IdType="doi">10.1177/03000605231154749</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chinese Rheumatology Association; National Clinical Research Center for Dermatologic and Immunologic Diseases; Chinese Systemic Lupus Erythematosus Treatment and Research Group. [2020 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus]. Zhonghua Nei Ke Za Zhi 2020; 59: 172&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">32146743</ArticleId></ArticleIdList></Reference><Reference><Citation>Keeling SO, Vandermeer B, Medina J, et al.. Measuring disease activity and damage with validated metrics: a systematic review on mortality and damage in systemic lupus erythematosus. J Rheumatol 2018; 45: 1448&#x2013;1461.</Citation><ArticleIdList><ArticleId IdType="pubmed">30111638</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xf6;rner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet 2019; 393: 2344&#x2013;2358.</Citation><ArticleIdList><ArticleId IdType="pubmed">31180031</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Alunno A, et al.. 2019 Update of the EULAR Recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019; 78: 736&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pubmed">30926722</ArticleId></ArticleIdList></Reference><Reference><Citation>Harry O, Crosby LE, Smith AW, et al.. Self-management and adherence in childhood-onset systemic lupus erythematosus: what are we missing? Lupus 2019; 28: 642&#x2013;650.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6506349</ArticleId><ArticleId IdType="pubmed">30907294</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams EM, Egede L, Faith T, et al.. Effective Self-Management Interventions for Patients With Lupus: Potential Impact of Peer Mentoring. Am J Med Sci 2017; 353: 580&#x2013;592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6249683</ArticleId><ArticleId IdType="pubmed">28641721</ArticleId></ArticleIdList></Reference><Reference><Citation>Twumasi AA, Shao A, Dunlop-Thomas C, et al.. Exploring the Perceived Impact of the Chronic Disease Self-Management Program on Self-Management Behaviors among African American Women with Lupus: A Qualitative Study. ACR Open Rheumatol 2020; 2: 147&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7077773</ArticleId><ArticleId IdType="pubmed">32037683</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira-Santos M, Verani JF, Camacho LA, et al.. Effectiveness of pharmaceutical care for drug treatment adherence in patients with systemic lupus erythematosus in Rio de Janeiro, Brazil: study protocol for a randomized controlled trial. Trials 2016; 17: 1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4818901</ArticleId><ArticleId IdType="pubmed">27038611</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira-Santos M, Verani JFS, Camacho LAB, et al.. Effectiveness of pharmaceutical care for drug treatment adherence in women with lupus nephritis in Rio de Janeiro, Brazil: a randomized controlled trial. Lupus 2019; 28: 1368&#x2013;1377.</Citation><ArticleIdList><ArticleId IdType="pubmed">31558100</ArticleId></ArticleIdList></Reference><Reference><Citation>Melchiors AC, Correr CJ, Venson R, et al.. An analysis of quality of systematic reviews on pharmacist health interventions. Int J Clin Pharm 2012; 34: 32&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">22183578</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin C, Zhang CG, Shu LY, et al.. Current status of knowledge-attitude-practice of patients with long-term oral administration of glucocorticoids in the rheumatic immunology department and the pharmaceutical monitoring. Chin J Hosp Pharm 2020; 40: 1020&#x2013;1026.</Citation></Reference><Reference><Citation>Niroomand M, Ghasemi SN, Karimi-Sari H, et al.. Diabetes knowledge, attitude and practice (KAP) study among Iranian in-patients with type-2 diabetes: A cross-sectional study. Diabetes Metab Syndr 2016; 10: S114&#x2013;S119.</Citation><ArticleIdList><ArticleId IdType="pubmed">26610404</ArticleId></ArticleIdList></Reference><Reference><Citation>Karbalaeifar R, Kazempour-Ardebili S, Amiri P, et al.. Evaluating the effect of knowledge, attitude and practice on self-management in patients with type 2 diabetes. Acta Diabetol 2016; 53: 1015&#x2013;1023.</Citation><ArticleIdList><ArticleId IdType="pubmed">27624577</ArticleId></ArticleIdList></Reference><Reference><Citation>Mustafa RE, Mushtaq S, Akhtar N, et al.. Assessment of knowledge, attitude and practice towards hepatitis among patients visiting the hepatitis clinic in tertiary care hospital, Rawalpindi, Pakistan. J Pak Med Assoc 2019; 69: 1136&#x2013;1141.</Citation><ArticleIdList><ArticleId IdType="pubmed">31431767</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin Q, Chen R, Zhang Y, et al.. Clinical Evaluation and Implement of Grading Pharmaceutical Care on Patients with Asthma and COPD. Chin Pharm J 2017; 52: 1460&#x2013;1464.</Citation></Reference><Reference><Citation>Li YY, Liu R, Xu Y. Establishment of a hierarchical pharmaceutical care system for perioperative blood glucose management in diabetic patients based on retrospective study. Pharm Care Res 2020; 20: 28&#x2013;31.</Citation></Reference><Reference><Citation>Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.</Citation><ArticleIdList><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Elm E, Altman DG, Egger M, et al.. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007; 147: 573&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pubmed">17938396</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Iba&#xf1;ez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000[J]. J Rheumatol 2002; 29: 288&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>